Strides Pharma Science · NSE: STAR · BSE: 532531

Q4 FY25 results · Jan–Mar 2025

Strides Pharma Science reported revenue from operations of ₹1,190.39 crore (up 9.8% from Q4 FY24) and net profit of ₹85.62 crore (up 719.9% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY25	Q4 FY24	YoY	Q3 FY25	QoQ
Revenue from operations	1,190.39	1,084.04	+9.8%	1,153.67	+3.2%
Other income	11.98	(13.55)	Turned profit	5.62	+113.3%
Total income	1,202.37	1,070.49	+12.3%	1,159.28	+3.7%
Profit before share of associates & JVs and tax	103.25	78.20	+32.0%	112.89	−8.5%
Share of profit/(loss) of associates & JVs	3.13	(48.58)		0.95
Net profit for the period	85.62	10.44	+719.9%	90.04	−4.9%
Attributable to shareholders of the company	82.19	18.18	+352.2%	87.95	−6.5%
EPS, basic (₹)	8.92	1.98	+350.5%	9.56	−6.7%
Net margin (%)	7.2	1.0		7.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY25	Q4 FY24	YoY	Q3 FY25	QoQ
Revenue from operations	555.96	617.63	−10.0%	550.92	+0.9%
Other income	12.12	29.63	−59.1%	2.43	+399.3%
Total income	568.08	647.27	−12.2%	553.35	+2.7%
Profit before tax	28.32	52.78	−46.3%	21.38	+32.5%
Net profit for the period	16.13	53.66	−69.9%	14.94	+8.0%
EPS, basic (₹)	1.75	5.84	−70.0%	1.62	+8.0%
Net margin (%)	2.9	8.7		2.7

Consolidated

Filed with BSE: 22 May 2025, 20:27 IST
Board meeting: 22 May 2025
Period: 01 Jan 2025 to 31 Mar 2025
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 22 May 2025, 20:27 IST
Board meeting: 22 May 2025
Period: 01 Jan 2025 to 31 Mar 2025
Review status: Audited
Source: XBRL filing on BSE